

## Corrigendum

**Dosing down with biologic therapies: a systematic review and clinicians' perspective****Christopher J. Edwards<sup>1</sup>, Bruno Fautrel<sup>2,3</sup>, Hendrik Schulze-Koops<sup>4</sup>,  
Tom W.J. Huizinga<sup>5</sup> and Klaus Kruger<sup>6</sup>**

---

Rheumatology 2017;56:1847–1856.  
doi:10.1093/rheumatology/kew464

The author affiliations in this paper have been corrected online. The correct affiliation numbers are also given above.

<sup>1</sup>Musculoskeletal Research Unit, NIHR Wellcome Trust Clinical Research Facility, University Hospital Southampton NHS Foundation Trust, Southampton, UK, <sup>2</sup>Pierre et Marie Curie University Paris 6, Sorbonne Universités, Pierre Louis Institute of Epidemiology and Public Health, Paris, GRC-08 (EEMOIS), <sup>3</sup>APHP, Rheumatology Department, Pitié Salpêtrière Hospital, Paris, F-75013, France, <sup>4</sup>Division of Rheumatology and Clinical Immunology, Department of Medicine IV, Ludwig-Maximilians- Universität, Munich, Germany, <sup>5</sup>Department of Rheumatology, Leiden University Medical Center, Leiden, C1-41, The Netherlands and <sup>6</sup>Rheumatologisches Schwerpunktzentrum, Munich, Germany

Correspondence to: Christopher J. Edwards, Musculoskeletal Research Unit, University Hospital Southampton NHS Foundation Trust, Mailpoint 63, G Level, West Wing Southampton General Hospital Southampton, SO16 6YD, UK.  
E-mail: cedwards@soton.ac.uk